CRL NYSE
Charles River Laboratories International, Inc.
1W: -0.2%
1M: -14.1%
3M: -6.0%
YTD: -21.5%
1Y: +10.7%
3Y: -15.6%
5Y: -51.7%
$160.30
+1.44 (+0.91%)
Weekly Expected Move ±8.0%
$127
$139
$151
$163
$175
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?
Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus
Charles River (CRL) Reliance on International Sales: What Investors Need to Know
Most healthcare companies report higher Y/Y EPS in strong earnings week
LH vs. CRL: Which Stock Is the Better Value Option?
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results
Charles River (CRL) Q1 2026 Earnings Transcript
Charles River reaffirms 2026 EPS $10.80-$11.30, targets ~120-150 bps margin expansion as divestitures close
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
Charles River (CRL) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
Charles River Gears Up for Q1 Earnings: What's in the Cards?
William Blair updates conviction stock list
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Here's Why Charles River Laboratories (CRL) is a Strong Value Stock
What is Zacks Research’s Forecast for CRL Q3 Earnings?
Charles River Laboratories International, Inc. $CRL Shares Purchased by Assetmark Inc.
OpenAI launches GPT-Rosalind, an AI model for life sciences research
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Massachusetts Financial Services Co. MA Takes Position in Charles River Laboratories International, Inc. $CRL
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of “Moderate Buy” from Brokerages
Aberdeen Group plc Purchases 88,853 Shares of Charles River Laboratories International, Inc. $CRL
Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL
Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus
Assenagon Asset Management S.A. Increases Stake in Charles River Laboratories International, Inc. $CRL
Contravisory Investment Management Inc. Takes $1.22 Million Position in Charles River Laboratories International, Inc. $CRL
CIBC Private Wealth Group LLC Sells 5,141 Shares of Charles River Laboratories International, Inc. $CRL
Why Is Charles River (CRL) Down 6.8% Since Last Earnings Report?
FDA issues guidance on alternatives to animal testing
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and CVS Health in focus
Algert Global LLC Buys 39,586 Shares of Charles River Laboratories International, Inc. $CRL
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of “Moderate Buy” by Brokerages
Research Analysts Offer Predictions for CRL Q1 Earnings
Zacks Research Has Bullish Forecast for CRL Q2 Earnings
Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL
Cresset Asset Management LLC Has $1.36 Million Stock Position in Charles River Laboratories International, Inc. $CRL
Dimensional Fund Advisors LP Purchases 120,207 Shares of Charles River Laboratories International, Inc. $CRL
Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc.
Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus
Charles River announces divestitures, updates guidance
Charles River raises annual profit view as it sells underperforming assets
Charles River Laboratories Provides Update on Planned Divestitures
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
What Analyst Projections for Key Metrics Reveal About Charles River (CRL) Q4 Earnings
Here's How Charles River Stock Is Placed Ahead of Q4 Earnings
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Penserra Capital Management LLC Makes New Investment in Charles River Laboratories International, Inc. $CRL
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Charles River Laboratories International, Inc. $CRL
Charles River Laboratories International, Inc. $CRL Shares Acquired by Cooke & Bieler LP
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
Charles River Enters Manufacturing Collaboration with Gazi University
Inscription Capital LLC Acquires 3,827 Shares of Charles River Laboratories International, Inc. $CRL
Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River to buy Cambodia-based monkey supplier for $510 million
Charles River Laboratories Provides Business Updates
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
Telix (TLX) 2-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
What Makes Charles River (CRL) a New Buy Stock
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
Telix (TLX) 4-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
TLX 5-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
TLX 7-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
TLX CLASS ACTION DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
TLX 11-DAY DEADLINE ALERT: Hagens Berman Urges Telix (TLX) Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
TLX CLASS ACTION DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Assenagon Asset Management S.A. Trims Holdings in Charles River Laboratories International, Inc. $CRL
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week High Following Analyst Upgrade
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
Federated Hermes Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Edgestream Partners L.P. Invests $1.80 Million in Charles River Laboratories International, Inc. $CRL
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of “Moderate Buy” from Brokerages
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain